Prognosis of patients with advanced bile tract carcinoma: assessment using the modified-Gustave Roussy Immune Score (mGRIm-s) as a clinico-immunological tool
Journal of Cancer Research and Clinical Oncology · 2024
DOI: 10.1007/s00432-024-05771-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2024. Verfasst von Yue Ma und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medical School of Chinese PLA, Beijing, 100853, China. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Biliary Tract Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The emergence of immune checkpoint inhibitors (ICIs) has enhanced survival outcomes for certain patients with advanced biliary tract carcinoma (BTC). Pinpointing those who would benefit most from immunotherapy remains elusive. We investigated the predictive value of the modified Gustave Roussy Immune Score (mGRIm-s) in BTC patients treated with ICIs.
Methods
Data from 110 patients at Chinese People's Liberation Army General Hospital, spanning September 2015 to April 2021, were analyzed. The median follow-up duration was 38.7 months as of December 2023. Risk factors included low albumin, high lactate dehydrogenase, and an elevated neutrophil–lymphocyte ratio. Patients were stratified into low (patients with no risk factors) and high (patients with at least one risk factor) mGRIm-s groups based on these factors.
Results
Survival outcomes post-immunotherapy favored the low mGRIm-s group, with significantly improved progression-free survival (PFS) and overall survival (OS) (8.50 months vs. 3.70 months and 21.60 months vs. 8.00 months). COX regression confirmed an elevated risk in the high mGRIm-s group. Subgroup analysis highlighted a notable survival advantage for low mGRIm-s patients receiving first-line immunotherapy.
Conclusions
This study underscores mGRIm-s's potential in predicting immunotherapy response in BTC, paving the way for more targeted approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical School of Chinese PLA, Beijing, 100853, China.
- Department of Medical Oncology, the First Medical Centre, Chinese PLA General Hospital, Beijing, 100853, China.
- Department of Medical Oncology, the Fifth Medical Centre, Chinese PLA General Hospital, Beijing, 100039, China.
- Yingtan City People's Hospital, Yingtan, 335000, China.
- Medical School of Chinese PLA, Beijing, 100853, China. daiguanghai@301hospital.com.cn.
- Department of Medical Oncology, the First Medical Centre, Chinese PLA General Hospital, Beijing, 100853, China. daiguanghai@301hospital.com.cn.
Zitieren
APA
Ma, Y., Pan, Y., Li, Y., Guan, H., & Dai, G. (2024). Prognosis of patients with advanced bile tract carcinoma: assessment using the modified-Gustave Roussy Immune Score (mGRIm-s) as a clinico-immunological tool. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-024-05771-w
Vancouver
Ma Y, Pan Y, Li Y, Guan H, Dai G. Prognosis of patients with advanced bile tract carcinoma: assessment using the modified-Gustave Roussy Immune Score (mGRIm-s) as a clinico-immunological tool. Journal of Cancer Research and Clinical Oncology. 2024. doi:10.1007/s00432-024-05771-w
BibTeX
@article{Ma2024,
author = {Ma, Yue and Pan, Yuting and Li, Yue and Guan, Huafang and Dai, Guanghai},
title = {Prognosis of patients with advanced bile tract carcinoma: assessment using the modified-Gustave Roussy Immune Score (mGRIm-s) as a clinico-immunological tool},
journal = {Journal of Cancer Research and Clinical Oncology},
year = {2024},
doi = {10.1007/s00432-024-05771-w}
}
EUVIMED